Rani Therapeutics Q3 net loss decreases, extends cash runway into 2028
Rani Therapeutics reported a Q3 net loss of $7.9 million, down from $12.7 million in Q3 2024. The company completed a $60.3 million oversubscribed private placement, extending its cash runway into 2028. Rani plans to initiate a Phase 1 trial for RT-114 by the end of 2025. Analysts maintain a "buy" rating on the stock, with a median 12-month price target of $10.50, representing a 76.2% upside from its recent closing price of $2.50.
)
Overview
- Rani announced $1.085 bln collaboration with Chugai for oral therapy development
- Completed $60.3 mln oversubscribed private placement, extending cash runway into 2028
- Net loss for Q3 2025 decreases to $7.9 mln from $12.7 mln in Q3 2024
Outlook
- Rani plans to initiate Phase 1 trial for RT-114 by end of 2025
- Company expects cash runway to extend into 2028
Result Drivers
- OVERSUBSCRIBED PRIVATE PLACEMENT - $60.3 mln private placement led by Samsara BioCapital supports financial stability
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Net -$7.91
Income mln
Q3 $7.26
Operatin mln
g
Expenses
Q3 -$7.26
Operatin mln
g Income
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 3 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for Rani Therapeutics Holdings Inc is $10.50, about 76.2% above its November 5 closing price of $2.50
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
